162 related articles for article (PubMed ID: 24921213)
1. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
Wang W; Jiang CY; Wang HW
J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
[No Abstract] [Full Text] [Related]
2. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
Miki M; Kawabe K; Igarashi H; Abe T; Ohishi Y; Hashimoto R; Karashima T; Yamasaki I; Inoue K; Ito T; Ogawa Y
Intern Med; 2018 Jul; 57(14):2007-2011. PubMed ID: 29491307
[TBL] [Abstract][Full Text] [Related]
3. [Pancreatic neuroendocrine tumors and von Hippel-Lindau disease].
Musso C; Paraf F; Petit B; Archambeaud-Mouveroux F; Valleix D; Labrousse F
Ann Pathol; 2000 Mar; 20(2):130-3. PubMed ID: 10740008
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
Tsimafeyeu I
J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
[TBL] [Abstract][Full Text] [Related]
5. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
Williams C; Walther M
ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib for advanced pancreatic neuroendocrine tumors.
Hubner RA; Valle JW
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
[TBL] [Abstract][Full Text] [Related]
7. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
Spiegel AM; Libutti SK
Nat Rev Clin Oncol; 2011 May; 8(5):258-9. PubMed ID: 21448150
[No Abstract] [Full Text] [Related]
9. Response to Somatostatin Analog Therapy in a Patient With von Hippel-Lindau Disease and Multiple Pancreatic Neuroendocrine Tumors.
OʼToole SM; Drake WM
Pancreas; 2017 Aug; 46(7):e57. PubMed ID: 28697140
[No Abstract] [Full Text] [Related]
10. Advances in pancreatic neuroendocrine tumor treatment.
Castellano D; Grande E; Barriuso J
N Engl J Med; 2011 May; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
[No Abstract] [Full Text] [Related]
11. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
[TBL] [Abstract][Full Text] [Related]
12. Late recurrence after surgical resection of a pancreatic tumor in von Hippel-Lindau disease.
Corleto VD; Cotesta D; Petramala L; Panzuto F; Pagnini C; Masoni L; Verrienti A; Delle Fave G; Filetti S; Letizia C
JOP; 2009 Sep; 10(5):562-5. PubMed ID: 19734639
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
Huda MS; Amiel SA; Ross P; Aylwin SJ
Diabetes Care; 2014; 37(5):e87-8. PubMed ID: 24757248
[No Abstract] [Full Text] [Related]
14. Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
Zugazagoitia J; Sastre J; Barrera J; García B; Díaz-Rubio E
J Cancer Res Ther; 2012; 8(2):303-5. PubMed ID: 22842382
[TBL] [Abstract][Full Text] [Related]
15. Advances in pancreatic neuroendocrine tumor treatment.
van der Veldt AA; Kleijn SA
N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
[No Abstract] [Full Text] [Related]
16. New target therapies for patients with neuroendocrine tumors of the pancreas.
Baltogiannis G; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
[No Abstract] [Full Text] [Related]
17. Promising advances in the treatment of malignant pancreatic endocrine tumors.
Jensen RT; Delle Fave G
N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
[No Abstract] [Full Text] [Related]
18. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
19. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
20. Advances in pancreatic neuroendocrine tumor treatment.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 May; 364(19):1871-2; author reply 1873-4. PubMed ID: 21561357
[No Abstract] [Full Text] [Related]
[Next] [New Search]